PT-141, known generically as bremelanotide, holds a distinction no other research peptide can claim: it has completed Phase III trials, received FDA approval, and is available as a prescription medication in the US. Under the brand name Vyleesi, it was approved on June 21, 2019, for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. That regulatory history gives it a different evidence profile than most peptides in this space — and a more nuanced story about what FDA approval does and doesn't mean.
Key Takeaways
- —Bremelanotide (Vyleesi/PT-141) received FDA approval June 2019 for HSDD in premenopausal women — the only peptide approved for any sexual dysfunction indication.
- —Mechanism: melanocortin-4 receptor (MC4R) agonist, acting centrally on CNS pathways involved in sexual motivation — not via vascular dilation like PDE5 inhibitors.
- —Phase III RECONNECT trial: 25% of bremelanotide patients vs 17% placebo achieved a meaningful increase in satisfying sexual events (SSEs); 50% vs 35% reported decreased distress (PMC, 2019).
- —Standard approved dose: 1.75 mg subcutaneous, 45 minutes before sexual activity; max once per 24 hours.
- —Off-label use in men is under active Phase II investigation for PDE5i-resistant erectile dysfunction (Palatin Technologies, 2024–2025).
Bremelanotide originated from research on melanotan II (MT-II), a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH). During clinical testing of MT-II as a potential tanning agent in the 1990s, researchers at the University of Arizona noticed a striking side effect: spontaneous erections in male study participants. That observation redirected research toward sexual function, producing a series of increasingly refined compounds — PT-141 being the candidate that advanced through clinical development.
PT-141 was originally tested as a nasal spray. The nasal formulation was abandoned when it was found to cause transient increases in blood pressure. The subcutaneous injection formulation (1.75 mg) became the approved delivery route — with a labelling requirement to avoid use in patients with cardiovascular disease or uncontrolled hypertension.
This distinction matters clinically. Sildenafil (Viagra), tadalafil (Cialis), and other PDE5 inhibitors work peripherally — they inhibit phosphodiesterase type 5 in smooth muscle tissue, increasing cGMP levels, causing vasodilation in genital tissue. They require existing sexual arousal to function; they don't generate desire.
Bremelanotide targets the CNS directly. It is a melanocortin-4 receptor (MC4R) agonist — it activates receptors in hypothalamic and limbic pathways involved in sexual motivation and arousal. Animal models of sexual behaviour show that MC4R activation increases proceptive behaviours (approach, solicitation) that precede physical sexual function. In humans, the proposed mechanism is modulation of desire and arousal at the neurological level, not vascular response downstream.
This means PT-141 theoretically addresses a different layer of the problem. PDE5 inhibitors address the hydraulic mechanics of erection. PT-141 addresses the motivational signal that initiates arousal. For patients with HSDD — characterised by persistent absence of sexual desire causing personal distress — PDE5 inhibitors are irrelevant; melanocortin-pathway modulation is the pharmacological target.
The Phase III RECONNECT trial enrolled 1,247 premenopausal women with HSDD diagnosed by the validated Female Sexual Dysfunction Index (FSFI). Participants used bremelanotide (1.75 mg subcutaneous) or placebo on demand over 52 weeks.
Primary endpoints:
What to make of the numbers: The absolute efficacy signal is small. The FDA approved bremelanotide based on statistical significance across both coprimary endpoints, combined with a strong safety profile and the existence of a genuine unmet need (no other approved pharmacotherapy for HSDD in women existed). The response rate — 25% vs 17% on SSEs — means approximately 12 people would need to be treated for one to benefit on that endpoint.
According to the long-term safety and efficacy analysis published in Fertility and Sterility (2019), bremelanotide demonstrated a consistent, statistically significant improvement in sexual desire and distress outcomes over 52 weeks, with a safety profile characterised primarily by transient nausea (40.1% vs 1.2% placebo) and flushing (20.4% vs 3.4% placebo) (PMC, 2019).
The FDA approval covers only HSDD in premenopausal women. Men are using PT-141 off-label for erectile dysfunction and sexual dysfunction related to desire, not mechanics.
2024 open-label pilot: 21 men with various sexual dysfunctions received subcutaneous bremelanotide. 80% reported being more satisfied with sexual experiences on at least two occasions. No control group — this is an observational report, not a trial.
Palatin Technologies Phase II (2024–2025): The most rigorous current human study in men. Palatin is testing a co-formulation of bremelanotide and a PDE5 inhibitor in a single subcutaneous injection for men who fail to respond to PDE5 inhibitors alone. Topline data was expected late 2024, with Phase III planning in 2025 if positive. This would be the first RCT-level evidence in men.
Historical erectile dysfunction data: Earlier bremelanotide studies in men (pre-2006, when the nasal formulation was under investigation) showed dose-dependent improvements in erectile response in both psychogenic and organic ED patients. These studies were conducted without a placebo control but showed clear dose-response curves.
Approved dose (women, HSDD):
Off-label research protocols (men):
The nausea issue: Nausea is the most common adverse effect, occurring in 40% of women in RECONNECT (vs 1.2% placebo). It typically begins 30–60 minutes post-injection and resolves within 2 hours. Ondansetron can be used prophylactically. Many practitioners start with a 0.5–1 mg test dose to establish individual tolerability.
| Parameter | Approved (Women) | Research (Men) |
|---|---|---|
| Dose | 1.75 mg SubQ | 1–2 mg SubQ |
| Timing | 45 min before | 30–60 min before |
| Frequency | Max 1×/24h; ~8×/month | Same caution applied |
| Main adverse effect | Nausea (40%), flushing (20%) | Similar profile |
Transient blood pressure elevation: Bremelanotide causes a transient mean increase of approximately 6 mmHg systolic and 4 mmHg diastolic, typically peaking 30–40 minutes post-injection and resolving within 12 hours. This was the reason the nasal spray was abandoned in early development. The subcutaneous formulation carries this same effect, leading to a contraindication in patients with cardiovascular disease or uncontrolled hypertension.
FDA black box / labelling: Bremelanotide is contraindicated in patients with known CV disease (arrhythmias, coronary artery disease, stroke history, uncontrolled hypertension). It should not be combined with alcohol, which can potentiate nausea.
No hormonal effects: Unlike GHRPs or GH secretagogues, bremelanotide does not affect the hypothalamic-pituitary-gonadal or HPA axis at therapeutic doses. It does not alter testosterone, estrogen, LH, FSH, cortisol, or ACTH.
PT-141's FDA-approved status means it can be legally prescribed — but that doesn't mean every source selling it is legitimate, or that every formulation is equivalent. The Next Pep peptide library covers bremelanotide's MC4R mechanism, pharmacokinetics, clinical trial history, and the critical differences between the FDA-approved Vyleesi formulation and off-label research variants in one verified reference.
Use the comparison tool to put PT-141 alongside other compounds you're researching — especially if you're evaluating its mechanism against PDE5 inhibitors or other melanocortin-pathway compounds. Next Pep is the neutral, non-commercial source for this data — no vendor conflict of interest, just the published evidence.
Yes. Vyleesi is the FDA-approved brand name for bremelanotide (PT-141), 1.75 mg subcutaneous, for treating HSDD in premenopausal women. PT-141 is the research name for the same molecule.
PDE5 inhibitors like sildenafil (Viagra) work peripherally — they increase blood flow to genital tissue but require sexual arousal to be present first. Bremelanotide acts centrally via melanocortin-4 receptors in the brain, modulating sexual desire and arousal at the neurological level. It doesn't primarily work through vascular mechanisms.
The most common are transient nausea (40% in Phase III), flushing (20%), and a mild transient blood pressure increase. Nausea typically peaks 30–60 minutes post-injection and resolves within 2 hours. Prophylactic ondansetron can help. The blood pressure effect is why the drug is contraindicated in cardiovascular disease patients.
FDA approval is for women only. Small pilot studies and off-label use in men have been published, showing improvements in desire and erectile function. Palatin Technologies is running a Phase II trial in PDE5-inhibitor non-responders in 2024–2025. No RCT in men has been completed as of 2026.
Clinical reports suggest additive or synergistic effects. Palatin's Phase II trial is specifically investigating a bremelanotide + PDE5 inhibitor combination formulation. Combining the two without medical supervision is not recommended given the blood pressure dynamics of both drug classes.
This article is for research and educational purposes only. Bremelanotide (Vyleesi/PT-141) is a prescription medication. Consult a licensed healthcare professional before use.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
A head-to-head comparison of BPC-157 and TB-500 covering mechanism, tissue specificity, dosing frequency, human evidence, and whether stacking them adds anything the literature actually supports.
Ipamorelin is a ghrelin-receptor agonist; CJC-1295 is a GHRH analog. Their mechanisms are complementary, which is why protocols typically stack them. This guide covers what each does alone, what stacking adds, and the DAC vs non-DAC distinction.